Journal article

N-terminal pro-B-type Natriuretic Peptides' Prognostic Utility Is Overestimated in Meta-analyses Using Study-specific Optimal Diagnostic Thresholds

Danielle Potgieter, Dale Simmers, Lisa Ryan, Bruce M Biccard, Giovanna A Lurati-Buse, Daniela M Cardinale, Carol PW Chong, Miloslaw Cnotliwy, Sylvia I Farzi, Radmilo J Jankovic, Wen Kwang Lim, Elisabeth Mahla, Ramaswamy Manikandan, Anna Oscarsson, Michael P Phy, Sriram Rajagopalan, William J Van Gaal, Marek Waliszek, Reitze N Rodseth

ANESTHESIOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015

Abstract

BACKGROUND: N-terminal fragment B-type natriuretic peptide (NT-proBNP) prognostic utility is commonly determined post hoc by identifying a single optimal discrimination threshold tailored to the individual study population. The authors aimed to determine how using these study-specific post hoc thresholds impacts meta-analysis results. METHODS: The authors conducted a systematic review of studies reporting the ability of preoperative NT-proBNP measurements to predict the composite outcome of all-cause mortality and nonfatal myocardial infarction at 30 days after noncardiac surgery. Individual patient-level data NT-proBNP thresholds were determined using two different methodologies. First, a s..

View full abstract

Grants

Funding Acknowledgements

Dr. Mahla has spoken for and received consulting fees from CLS Behring Biotherapies for Life (Vienna, Austria), Astra Zeneca (Vienna, Austria), and Boehringer Ingelheim (Ingelheim, Germany). She has received study grants from CLS Behring Biotherapies for Life and Novo Nordisk Pharma GmbH (Vienna, Austria). The other authors declare no competing interests.